<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
Bio-Plexus, Inc.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, without par value
- -------------------------------------------------------------------------------
(Title of Class of Securities)
09057C 106
- -------------------------------------------------------------------------------
(CUSIP Number)
Walter W. Simmers, Esq., Pepe & Hazard LLP, Goodwin Square, Hartford, CT 06103
(860) 241-2643
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
February 3, 1999
- -------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission, See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 09057C106 PAGE 2 OF 3 PAGES
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David Himick
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /X/
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)
Not Applicable
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 1,454,134 shares of Common Stock (includes right to
acquire through exercise of warrants 77,000 shares
of Common Stock)
BENEFICIALLY ------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 145,378 shares of Common Stock
PERSON ------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
1,454,134 shares of Common Stock (includes right to
acquire through exercise of warrants 77,000
shares of Common Stock)
------------------------------------------------------
10 SHARED DISPOSITIVE POWER
145,378 shares of Common Stock
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,599,512 (includes right to acquire through exercise of warrants 77,000
shares of Common Stock)
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
Not applicable
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.0%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
Page 3 of 3
Item 1. SECURITY AND ISSUER
Common Stock, without par value
Bio-Plexus, Inc., 129 Reservoir Rd., Vernon, Connecticut 06066
Item 2. IDENTITY AND BACKGROUND
(a) David Himick (and Faith Himick with respect to
shared beneficial ownership of certain shares)
(b) c/o Bio-Plexus, Inc., 129 Reservoir Rd., Vernon,
Connecticut 06066
(c) Director of Bio-Plexus, Inc.
(d) N/A
(e) N/A
(f) USA
Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Personal funds of $250,000 paid for 124,378 shares of Common Stock
on September 11, 1998. Personal funds of $1,000,000 paid for 500,000
shares of Common Stock pursuant to purchase agreement dated February
3, 1999. 2,500 shares of Common Stock and warrants to purchase
75,000 shares of Common Stock, which are immediately exercisable at
a price of $2.00 per share, were acquired by grant under the same
purchase agreement. In April 1997 and June 1997, acquired warrants
to purchase an aggregate of 2,000 shares of Common Stock, which
became exercisable in increments of 1,000 shares in April 1998 and
June 1998 at prices of $5.00 and $3.00, respectively, as
compensation as a non-employee director.
Item 4. PURPOSE OF TRANSACTION
The securities were acquired in the ordinary course of business and
not with the purpose or the effect of changing or influencing the
control of the Issuer.
Item 5. INTEREST IN SECURITIES OF THE ISSUER
The information required by this Item is disclosed in Sections 7
through 11, inclusive, of the cover page of this Schedule 13D and
Items 2 and 3 of this Schedule 13D.
Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIP WITH RESPECT
TO SECURITIES OF THE ISSUER
Faith Himick is the spouse of David Himick.
Item 7. MATERIALS TO BE FILED AS EXHIBITS
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
March 10, 1999 /s/ David Himick
- ----------------- ------------------------------
Date Signature
David Himick, Director
-----------------------------
Name/Title